INTRODUCTION {#sec1-1}
============

CKD is an independent risk factor cardiovascular morbidity and mortality (CVD), even after adjustment for traditional and non-traditional risk factors. CVD events like cerebrovascular accident (CVA), ischeamic heart disease (IHD), congestive cardiac failure (CCF) and peripheral vascular disease (PVD) are much higher in CKD population.[@ref1]

Traditional risk factors like hypertension, diabetes, hyperlipideamia and male gender cannot explain the abnormally high incidence of CVD in ESRF patients. The mortality rate for dialysis patients is abnormally high, up 10 to 30 times higher than the matched population.[@ref1]

Several theories have been proposed over the last decade over the role of traditional and non-traditional contributing factors in accelerating CVD in ESRF population. However all these studies were done abroad with considerable different ethnic origin.

In this study, we have undertaken a local study to evaluate whether we could predict the CVD risk for our local ESRF patients by using the routine parameters that are easily available in our day to day clinical practice. We hope by identifying these factors, we can institute strategy that will lessen the CVD risks in ESRF patients.

METHODS {#sec1-2}
=======

This was a retrospective, cross-sectional, single center study. Incident ESRF patients undergoing Haemodialysis (HD) and Chronic Ambulatory Peritoneal Dialysis (CAPD) at Serdang Hospital from April 2006 until April 2009 were recruited by means of universal sampling. ESRF patients were defined as those having Glomerular Filtration Rate (GFR) \< 15ml/min and have been started on dialysis for three months duration. The renal replacement therapy is of either haemodialysis or peritoneal dialysis. ESRF patients who had changed their dialysis modalities, either from HD to CAPD or vice versa or new ESRF of less than three months were excluded and those who had renal transplantation done were excluded.

Data were collected by three trained researchers that reviewed the hospital electronic medical records of the recruited ESRF patients. The collected data that were entered into a proforma which capture data like socio-demographic factors, baseline medical history, essential routine laboratory parameters and the occurrence of new CV events.

This study was non-interventional and did not influence the nature of treatment received by the subjects. Institutional review board (IRB) approval was obtained and either the patients or patients' closest available next-of-kin were approached in all cases for informed consent using IRB-approved informed consent form. This was an investigator- initiated study.

Data was analysed using SPSS version 18.0. The normality of continuous data was tested using Kolmogorov-Smirnov test. χ² test was used to test for the association of categorical data and p value ≤0.05 was considered significant. For continuous data which was not normally distributed, Mann-Whitney U test was used to test for the association. For dichotomous outcomes such as the CV events, Multiple Logistic Regression was used to determine the absolute risk on incidence.

RESULTS {#sec1-3}
=======

A total of 136 of dialysis patients were recruited into the study. [Table-I](#T1){ref-type="table"} shows the demographic, laboratory parameters and the new CV events. Majority of the patients were within the 65-74 age group. The most common cause of ESRF in our center was diabetic nephropathy. The co-morbidities documented were hypertension (96.5%), diabetes (66.2%), hyperlipidemia (58.1%) and pre-existing cardiovascular event (31.6%).

###### 

Summary demographic, laboratory parameters, and cardiovascular events (n=136).

  Variables                         Frequency (%)   Mean          Median ± IQR   
  --------------------------------- --------------- ------------- -------------- --
  Socio-demographic Factors                                                      
  Age                                               50.96         55 ± 20        
   15-34                            22 (16.2)                                    
   35-54                            44 (32.4)                                    
   55-74                            66 (33.1)                                    
   ≥75                              4 (2.9)                                      
  Gender                                                                         
   Male                             68 (50.0)                                    
   Female                           68 (50.0)                                    
  Race                                                                           
   Malay                            70 (51.5)                                    
   Chinese                          48 (35.3)                                    
   Indian                           18 (13.2)                                    
  Causes of ESRD                                                                 
   DM                               45 (33.1)                                    
   DM + HPT                         32 (23.5)                                    
   Unknown                          24 (17.6)                                    
   HPT                              15 (11.1)                                    
   GN                               2 (1.5)                                      
   SLE                              1 (0.7)                                      
  Co-morbidities                                                                 
   HPT                              130 (95.6)                                   
   DM                               90 (66.2)                                    
   Hyperlipidaemia                  79 (58.1)                                    
   Pre-existing CV event            43 (31.6)                                    
  Essential Laboratory Parameters                                                
  Lipid Profile                                                                  
   Total Cholesterol (mmol/L)                       5.17 ± 1.70                  
   LDL (mmol/L)                                                   3.11 ± 1.47    
   HDL (mmol/L)                                                   1.15 ± 0.40    
   Triglyceride (mmol/L)                                          1.86 ± 1.29    
  Serum Calcium (mmol/L)                                          2.19 ± 0.31    
  Serum Phosphate (mmol/L)                          1.42 ± 0.53                  
  Random Blood Glucose (mmol/L)                     8.18 ± 5.50                  
  Haemoglobin (g/dL)                                              10.40 ± 2.40   
  Cardiovascular Event                                                           
   CV event (overall)               37 (27.2)                                    
   CVA                              12(8.8)                                      
   IHD                              7(5.1)                                       
   CCF                              2(1.5)                                       
   PVD                              16(11.8)                                     

\*DM: Diabetes Mellitus, HPT: Hypertension, GN: Glomerulonephritis, SLE: Systemic Lupus Erythematosus,

LDL: Low density lipoprotein, HDL: High density lipoprotein, CVA: Cerebral vascular accident,

IHD: Ischaemic heart disease, CCF: congestive cardiac failure, PVD: peripheral vascular disease.

In the bivariate analysis results, there were significant association between hypertensive nephrosclerosis (p=0.040), diabetes mellitus (p=0.050) and pre-existing CVD (p=0.024) with the occurrence of new CVD events ([Table-II](#T2){ref-type="table"}). As for laboratory tests, there were significant associations between LDL (p=0.043) and random blood glucose (p=0.014) level with the occurrence of new CVD events ([Table-III](#T3){ref-type="table"}).

###### 

Bivariate analysis of baseline medical history with cardiovascular events.

  Baseline Medical History    CV Events   χ^2^ value/Fisher's Exact Test   p value                                                               
  --------------------------- ----------- -------------------------------- --------- -------- --------- ---------------------------------------- ---------------------------------------
  *Causes of ESRD*                                                                                                                               
  Unknown                     Yes         1                                (4.2)     23       (95.8)    ^[b](#t2f3){ref-type="table-fn"}^        0.304
  No                          15          (13.4)                           97        (86.6)                                                      
  DM                          Yes         12                               (14.8)    69       (85.2)    1.795^[a](#t2f2){ref-type="table-fn"}^   0.180
  No                          4           (7.3)                            51        (92.7)                                                      
  GN                          Yes         1                                (25.0)    3        (75.0)    ^[b](#t2f3){ref-type="table-fn"}^        0.397
  No                          15          (11.4)                           117       (88.6)                                                      
  SLE                         Yes         0                                \(0\)     1        (100.0)   ^[b](#t2f3){ref-type="table-fn"}^        1.000
  No                          16          (11.9)                           119       (88.1)                                                      
  Polycystic kidney disease   Yes         0                                \-        0        \-        \-                                       \-
  No                          16          (11.8)                           120       (88.2)                                                      
  Obstructive nephropathy     Yes         0                                \(0\)     5        (100.0)   ^[b](#t2f3){ref-type="table-fn"}^        1.000
  No                          16          (12.2)                           115       (87.8)                                                      
  Hypertension                Yes         10                               (18.9)    43       (81.1)    4.221^[a](#t2f2){ref-type="table-fn"}^   0.040[\*](#t2f1){ref-type="table-fn"}
  No                          6           (7.2)                            77        (92.8)                                                      
  Others                      Yes         0                                \(0\)     12       (100.0)   ^[b](#t2f3){ref-type="table-fn"}^        0.359
  No                          16          (12.9)                           108       (87.1)                                                      
  *Co-morbidities*                                                                                                                               
  Hypetension                 Yes         15                               (11.5)    115      (88.5)    ^[b](#t2f3){ref-type="table-fn"}^        0.535
  No                          1           (16.7)                           5         (83.3)                                                      
  Diabetes Mellitus           Yes         14                               (15.6)    76       (84.4)    3.684^[a](#t2f2){ref-type="table-fn"}^   0.050[\*](#t2f1){ref-type="table-fn"}
  No                          2           (4.3)                            44        (95.7)                                                      
  Hyperlipidaemia             Yes         11                               (13.9)    68       (86.1)    0.847^[a](#t2f2){ref-type="table-fn"}^   0.357
  No                          5           (8.8)                            52        (91.2)                                                      
  Pre-existing CV             Yes         34                               (79.1)    9        (20.9)    5.089^[a](#t2f2){ref-type="table-fn"}^   0.024[\*](#t2f1){ref-type="table-fn"}
  No                          86          (92.5)                           7         (7.5)                                                       

p≤0.05 is significant

χ^2^ Test

Fisher's Exact Test.

###### 

Bivariate analysis of laboratory parameters and cardiovascular events.

  Lab Parameters                  CV Event       Median ± IQR   Mean Rank   Z value   p value
  ------------------------------- -------------- -------------- ----------- --------- ---------------------------------------
  Total Cholesterol (mmol/L)      Yes            4.45 ± 1.65    51.78       -1.807    0.071
  No                              5.21 ± 1.65    70.73                                
  LDL (mmol/L)                    Yes            2.51 ± 1.31    49.81       -0.202    0.043[\*](#t3f1){ref-type="table-fn"}
  No                              3.12 ± 1.51    70.99                                
  HDL (mmol/L)                    Yes            1.17 ± 0.37    76.16       -0.828    0.408
  No                              1.12 ± 0.41    67.48                                
  TG (mmol/L)                     Yes            1.94 ± 0.81    65.91       -0.280    0.779
  No                              1.84 ± 1.31    68.85                                
  Serum Calcium (mmol/L)          Yes            2.19 ± 0.25    77.69       -0.993    0.321
  No                              2.19 ± 0.32    67.28                                
  Serum Phosphate (mmol/L)        Yes            1.57 ± 0.50    82.38       -1.500    0.408
  No                              1.40 ± 0.55    66.65                                
  Random Blood Glucose (mmol/L)   Yes            9.46 ± 5.47    91.25       -2.459    0.014[\*](#t3f1){ref-type="table-fn"}
  No                              7.72 ± 5.25    65.47                                
  Haemoglobin (g/dL)              Yes            10.30 ± 1.73   72.91       -0.476    0.634
  No                              10.40 ± 2.75   67.91                                

p≤0.05 is significant Mann-Whitney U test.

Statistical analysis via multiple logistic regression showed history of pre-existing CV event (p=0.050), serum phosphate level (p=0.045) and random blood glucose level (p=0.035) were associated with significant increased of developing new CVD ([Table-IV](#T4){ref-type="table"}). Interestingly a high total cholesterol level with associated with a significant fewer CV events (P=0.035). There is no correlation between CVD events and serum haemoglobin and calcium level. Other comorbidities and aetiology of ESRF do not seem to have any correlation either with CVD events.

###### 

Multivariate analysis.

  Variables                    B        p value                                 Exp (B)   95.0% C.I. for Exp (B)   
  ---------------------------- -------- --------------------------------------- --------- ------------------------ ---------
  *Socio-demoraphic Factor*                                                                                        
   Gender                      -0.415   0.584                                   0.661     0.149                    2.920
  *Causes of ESRD*                                                                                                 
   Diabetes mellitus           -0.893   0.378                                   0.409     0.056                    2.981
   Hypertension                1.224    0.068                                   3.402     0.913                    12.685
  *Co-morbidities*                                                                                                 
   Hypertension                -1.487   0.300                                   0.226     0.014                    3.769
   Diabetes mellitus           1.704    0.170                                   5.498     0.482                    62.665
   Hyperlipidaemia             -0.227   0.762                                   0.797     0.184                    3.455
   Pre-existing CV event       1.417    0.050[\*](#t4f1){ref-type="table-fn"}   4.124     0.990                    17.187
  *Essential Lab Parameters*                                                                                       
   Total cholesterol           -0.597   0.036[\*](#t4f1){ref-type="table-fn"}   0.550     0.315                    0.963
   Serum calcium               2.128    0.159                                   8.397     0.434                    162.481
   Serum phosphate             1.769    0.045[\*](#t4f1){ref-type="table-fn"}   5.862     1.041                    33.024
   Random blood glucose        0.177    0.035[\*](#t4f1){ref-type="table-fn"}   1.193     1.012                    1.406
   Haemoglobin                 0.104    0.624                                   1.109     0.733                    1.679
  *Constant*                   -9.400   0.016                                   0.000                              

p≤0.05 is significant; Nagelkerke R Square=0.353

DISCUSSION {#sec1-4}
==========

There is abundance of data which demonstrated the association of ESRF and CVD.[@ref1] The overall prevalence of CVD in our center was 31.6% with incidence rate of 27.2%.

The aetiology of ESRF appeared to have positive correlation with CVD where diabetic nephropathy and hypertensive nephrosclerosis has the worst outcome as shown in the bivariate analysis. In a large, prospective cohort study that included 12 550 adults, the development of type II diabetes was almost 2.5 times as likely in persons with hypertension than in their normotensive counterparts. This, in conjunction with considerable evidence of the increased prevalence of hypertension in diabetic persons, suggests that these 2 common chronic diseases frequently coexist. Moreover, each pathophysiological disease entity, although independent in its own natural history, serves to exacerbate the other.[@ref2]

The bivariate analysis also demonstrated that an elevated random blood glucose level or low density lipoprotein (LDL) level significantly increased the cardiovascular risk. However further multivariate analysis demonstrated the inverse relationship with total cholesterol level and CVD. Our study supported the hypothesis whereby a lower plasma total cholesterol level in ESRF patient was associated with a significantly higher risk of death, possibility due to confounding protein-energy wasting or 'time discrepancy of competing risks' in which hypercholesterolaemia is beneficial only in the short term, while it worsens survival over a long-term interval.[@ref3] Cholesterol level reflects the nutritional status and well being of the ESRF patient a low cholesterol level is a results of malnutrition and on-going inflammation.[@ref4]

The multivariate analysis again reconfirmed the increase cardiovascular risks with elevated random sugar level and phosphate level. In a recently published meta-analysis and systemic analysis, a high glycated haemoglobin level significantly increased the mortality risk in ESRF patient on dialysis. Poor glycemic control might result directly in macrovascular complications, possibly secondary to the generation of advanced glycation end products (AGEs), and hence shorten survival of these patients.[@ref5]

In ESRD patients, as glomerular filtration rate decreases, there will be accumulation of inorganic phosphate which leads to stimulation of parathyroid hormone (PTH) in an attempt to restore the serum phosphorus and calcium homestasis. We found that hyperphosphatemia significantly increased risk of cardiovascular events by 5.8 times. Inadequate control of serum phosphorus contributed to elevated insoluble calcium-phosphorus (Ca x P) product, which lead to cardiovascular calcification, and accelerated CVD manifestation.[@ref6] In our study, there was no association between serum calcium level and occurrence of cardiovascular event in dialysis patients. The presence and extent of vascular calcifications rather than serum calcium were strong predictors of cardiovascular mortality.[@ref6]

In our study, there were 31.6% dialysis patients who had pre-existing cardiovascular event prior to initiation of dialysis treatment. In both bivariate and multivariate analysis, pre-existing CVD was statistically associated with cardiovascular event. Those with pre-existing cardiovascular disease also has 4.1 times risk of developing further cardiovascular complications. The pre-existence of CVD appeared to be a strong predictor for CVD event. This finding concurred with the findings done in Canada by Kalantar-Zadeh.[@ref7]

Majority of our patient has anaemia of chronic disease. Generally, patients with ESRD will develop anaemia mainly due to the inability of the kidneys to secrete enough erythropoietin to stimulate adequate hematopoiesis.[@ref8] Apart from erythropoietin deficiency, uremic-induced inhibitors of erythropoiesis, shortened erythrocyte survival, and disordered iron homeostasis all contribute to the development of anaemia. Recent work has identified hepcidin excess as a main contributor to the disordered iron homeostasis and anemia of CKD by impairing dietary iron absorption and iron mobilization from body stores.[@ref9]

From both the bivariate and multivariate analysis, our study showed there was no association between haemoglobin level and cardiovascular event. Patients with ESRD and mild-to-moderate anaemia, the normalization of heamoglobin levels to 13.0 to 15.0 g/dL did not reduce cardiovascular events.[@ref10]

We acknowledge that we have not studied all the potential risk factors but rather of those which are routinely available and easily carried out in our day to day practice. Our study is also limited by the sample size and it is a single center study which may not be accurate representation of the regional trend. Nevertheless this study reassured us that routine measurement and history taking is invaluable in determining the cardiovascular risk factors.
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